Assembly Biosciences Shares Fall 6.85% on $100M Fundraise and Rare Liver Disease Bet

Assembly Biosciences saw its stock drop 6.85% on Monday after unveiling a $100 million equity offering and a strategic broadening of its lead pipeline beyond hepatitis delta into two additional rare liver diseases. The financing, expected to close on May 26, 2026, gives the company the firepower to advance its oral NTCP inhibitor, ABI-6250, into three distinct indications: chronic hepatitis D (HDV), primary biliary cholangitis (PBC), and primary sclerosing cholangitis (PSC).

The therapeutic rationale hinges on a single molecular target. ABI-6250 blocks the sodium-taurocholate cotransporting polypeptide (NTCP), a membrane protein on liver cells that both recycles bile acids and serves as the entry point for the hepatitis D virus. By inhibiting NTCP, the compound seeks to reduce bile acid accumulation and the resulting inflammation in cholestatic diseases while simultaneously preventing HDV from infecting hepatocytes. PSC is a particularly high-stakes target — no approved therapy currently exists for the condition.

To fund the expanded clinical program, Assembly placed roughly 3.36 million shares at $26.50 each, supplemented by pre-funded warrants covering an additional 415,000 shares at $26.499 per warrant. Gross proceeds total approximately $100 million. Underwriters Guggenheim Securities, UBS Investment Bank, and Mizuho also have a 30-day option to buy up to about 566,000 additional shares to cover over-allotments. The investor syndicate includes Gilead Sciences, Commodore Capital, Farallon Capital Management, Seven Fleet Capital, and Sirenia Capital Management. Gilead has signaled a non-binding interest in maintaining its percentage ownership stake.

Should investors sell immediately? Or is it worth buying Assembly Biosciences?

The infusion will support a two-pronged clinical timeline: a Phase 2 study for ABI-6250 in HDV is set to begin in the fourth quarter of 2026, followed by a Phase 2 basket trial for PBC and PSC in the first quarter of 2027, subject to regulatory feedback. The U.S. Food and Drug Administration has already held what the company describes as a constructive pre-IND meeting regarding the cholestatic indications, though the final meeting minutes are still pending.

In the nearer term, all eyes will be on the EASL Congress in Barcelona on May 27, 2026. There, Edward J. Gane of the University of Auckland will present interim Phase 1a data from a randomized, blinded study in healthy volunteers. The dataset will cover safety, pharmacokinetics, and pharmacodynamics — with dose-dependent increases in plasma bile acids expected to serve as a direct biomarker of NTCP inhibition in the target tissue. Chronic toxicology studies have already been completed and support the planned long-term dosing in Phase 2.

The stock’s single-day retreat of 6.85% reflects the dilution from the new shares, but market watchers are likely to pay closer attention to the EASL readout. Positive safety and biomarker data could quickly shift focus from the financing mechanics to the scientific potential of ABI-6250 as a multipurpose therapy across a rare-disease liver portfolio.

Ad

Assembly Biosciences Stock: New Analysis - 26 May

Fresh Assembly Biosciences information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.

Read our updated Assembly Biosciences analysis...

en | US0453961080 | ASSEMBLY | boerse | 69418090 |